# A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

> **NCT00369070** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 186 (actual)

## Conditions studied

- Advanced Non-squamous NSCLC

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** AMG 706
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00369070
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01-31
- **Primary completion:** 2008-04-23
- **Final completion:** 2011-08-03
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2018-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369070, "A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00369070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*